Respironics' injunction against AirSep upheld:
This article was originally published in Clinica
An appellate court in the US has upheld Respironics' preliminary injunction in a patent infringement suit against AirSep. As a result, AirSep, of Buffalo, New York, is prohibited from manufacturing, distributing and selling any device which uses Respironics' bi-level airway pressure technology, including bi-level devices for the treatment of obstructive sleep apnoea. The decision affirms a ruling from November 1997 by the US district court for the Western District of Pennsylvania. Pittsburg, Pennsylvania-based Respironics is the market leader in the obstructive sleep apnoea treatment market.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.